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Abstract
Noscapine, a plant-derived, non-toxic, over-the-counter antitussive alkaloid has tubulin-binding properties. Based upon the
structural resemblance of noscapine to colchicine, a tubulin-binding anti-inflammatory drug, noscapine and its semi-
synthetic brominated analogs were examined for in vitro anti-inflammatory activity. Brominated noscapine analogs were
found to inhibit cytokine and chemokine release from macrophage cell lines but did not affect cell viability. Brominated
noscapine analogs demonstrated anti-inflammatory properties in both TLR- and non-TLR induced in vitro innate immune
pathway inflammation models, mimicking septic and sterile infection respectively. In addition, electron microscopy and
immunoblotting data indicated that these analogs induced robust autophagy in human macrophages. This study is the first
report to identify brominated noscapines as innate immune pathway anti-inflammatory molecules.
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Introduction
The innate immune system plays a crucial role in host defense
and homeostasis. Innate immune responses are induced when
pattern recognition receptors such as Toll-like receptors (TLR)
sense the presence of pathogen associated molecules (PAMPS) or
endogenous ‘‘danger’’ molecules (DAMPS) released by damaged
cells [1,2]. Although acute innate pathway inflammatory responses
promote termination of infection and wound healing, chronic
activation of this pathway can lead to tissue damage and fibrosis
and contribute to various disease states such as atherosclerosis,
arthritis, inflammatory bowel disease and even cancer [1,2,3].
There is a need for new non-toxic agents that can treat
inflammation. One class of anti-inflammatory agents is microtu-
bule-disrupting agents such as colchicine and vinblastine. These
agents have been shown to reduce TNFa production in
macrophages due to their ability to impair tubulin dynamics [3].
In particular, colchicine, a robust microtubule-depolymerizing
agent, has been widely employed for gout management. However,
toxicities limit colchicine’s usefulness [4]. Another tubulin inhibitor,
vinblastine, used in the treatment of hematological malignancies,
has significant toxic side-effects such as leucocytopenias, gastroin-
testinal toxicity, peripheral neuropathy and immunosuppression
[5]. Thus, the search for non-toxic microtubule-binding agents that
have anti-inflammatory activity continues.
Noscapinoids constitute an emerging class of small-molecule
microtubule-modulating agents that do not alter the total polymer
mass of tubulin [6,7,8,9,10]. The parent molecule, noscapine, a
plant-derived antitussive alkaloid has been recently found to have
anticancer activity [11,12,13]. Rational drug-design and chemical-
synthesis of potent noscapine analogs (noscapinoids) that retain the
non-toxic attributes of the parent noscapine and are more
efficacious in cancer cells has been reported [7,8,9,10]. Particu-
larly, brominated noscapine analogs [(S)-3-((R)-9-bromo-4-methoxy-
6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-6,7-di-
methoxyiso-benzofuran-1(3H)-one, referred to as 9-bromonoscapine or
Br-nos] and [(R)-9-bromo-5-((S)-4,5-dimethoxy-1,3-dihydroisobenzo-
furan-1-yl)-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]di-oxolo-[4,5-g]
isoquinoline, referred to as reduced-9-bromonoscapine or Red-Br-
nos] have been shown to have significant anticancer activity and
are non-toxic at doses as high as 300 mg/kg [9,10,14,15]. Perhaps
due to limited effects on microtubule dynamics, noscapinoids do
not perturb the transport functions of microtubules in a variety of
cell types such as post-mitotic neurons and have no apparent
histo-, hemato-, immuno- or neuronal toxicity [8,9,10,14,15,16].
Another unique property of noscapinoids is their oral bioavail-
ability [17]. Interestingly, a close look at molecular structure
reveals structural resemblance of noscapine to colchicine, in that
both have a common dimethoxy phenyl group (Figure 1). Based
upon this structural similarity, the aim of this study was to
investigate innate immune pathway anti-inflammatory activity of
noscapine and its brominated analogs in vitro. We describe the anti-
inflammatory activity of brominated noscapine analogs, 9-
bromonoscapine (Br-nos) and the cyclic ether brominated analog
(Red-Br-nos) in in vitro models mimicking septic and sterile innate
immune pathway induced inflammation. The data demonstrate
that these drugs inhibit TNFa, IL-8 and nitric oxide release upon
challenge with various TLR and non-TLR ligands. This is the first
report to identify and define the innate immune pathway anti-
inflammatory activity of noscapine and its brominated analogs.
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Brominated Noscapine Analogs Possess Potent Innate
Anti-Inflammatory Activity
Noscapine and brominated noscapine analogs (Br-nos and Red-
Br-nos) were first investigated in a TLR ligand induced septic
inflammation model. Human (THP-1) and murine (RAW 264.7)
macrophages were used that usually respond well to a diverse
repertoire of pathogens and inflammatory mediators. Macrophag-
es were treated with noscapine or brominated noscapine analogs
at 10, 25 and 50 mM prior to stimulation or co-stimulation with
highly purified TLR-ligands (meningococcal LPS, a TLR4-MD-2
ligand and the synthetic lipopetide Pam3CSK4, a TLR2 ligand).
Pre-treatment of murine RAW 264.7 and human THP-1
macrophages with brominated noscapine analogs (50 mM) for
4 hr followed by a 12 hr stimulation with the TLR4-MD-2 ligand
meningococcal LPS (doses 10-0.31 pM) resulted in a significant
reduction in nitric oxide and TNFa release compared to cells that
were treated with DMSO (untreated control) and stimulated with
LPS or Pam3CSK4 (Figure 2). Similar reduction in nitric oxide
and TNFa release was observed in time-course of drug pre-
treatment i.e. 1, 2 and 12 hrs (data not shown). Brominated
noscapine analogs displayed significantly higher anti-inflammatory
activity compared to the parent drug noscapine. Similarly, co-
treatment of human THP-1 and murine RAW 264.7 macrophages
with brominated noscapine analogs and TLR-ligands LPS and
Pam3CSK4 for 12 hr resulted in significant reduction of TNFa
and nitric oxide release (Figure 3). However, no effects on cell
viability as determined using trypan blue vital dye exclusion,
microscopic morphology and LDH release were observed in these
studies. THP-1 cells incubated for 48 hr with 50 mM of either
DMSO, Nos, Br-nos or Rd-Br-nos released 5, 7, 8 and 10 IU/L of
LDH, respectively. Noscapine or brominated noscapine analogs
alone did not induce inflammatory responses or impair cellular
viability in human or murine macrophages. The brominated
noscapine analogs dampened TLR-mediated TNFa and nitric
oxide (NO) release from human and murine macrophages in a
dose-dependent manner (Figure 4). In summary, these data
demonstrated significant innate immune anti-inflammatory activ-
ity of brominated noscapine analogs to TLR ligands compared to
untreated controls or the parent drug noscapine.
Anti-Inflammatory Potential of Brominated Noscapines in
Sterile Inflammation
The anti-inflammatory role of brominated noscapines was
also confirmed in a sterile inflammation model mimicked by
macrophages stimulated with recombinant cytokines and
chemokines instead of TLR ligands. Human and murine
m a c r o p h a g e sa sw e l la sH E K - T L Rt r a n s f e c t e dc e l l sw e r e
induced with non-TLR ligands such as the cytokine TNFa or
the chemokine IP-10/CXCL10. Brominated noscapine analogs
significantly reduced nitric oxide release from murine macro-
phages ScCr (TLR4-deficient cells) stimulated with recombinant
cytokine mouse TNFa (Figure 5A). Furthermore, brominated
noscapine analogs significantly decreased nitric oxide release
from murine RAW 264.7 (TLR4-sufficient cells) macrophages
induced with recombinant mouse chemokine IP-10/CXCL10
(Figure 5B).
Brominated Noscapine Analogs Do Not Bind TLR-4-MD-2
Receptor
To confirm the anti-inflammatory effects of brominated
noscapine analogs, HEK293 human epithelial cells stably-trans-
fected with TLR4-MD-2-CD14 receptors were co-treated with
noscapine analogs (50 mM)and varying LPSconcentration followed
by overnight incubation. Brominated noscapine analogs signifi-
cantly reduced TLR4-MD-2 mediated IL-8 release from HEK/
TLR4-MD-2-CD14 cells (Figure 6). These drugs also significantly
reduced IL-8 release by ,3 fold (no drug=1400 pg/ml, Br-
nos=650 pg/ml, Red-Br-nos=400 pg/ml) from HEK293 cells
transfected with TLR2 alone or TLR2/6 receptors induced with
Pam3CSK4. Brominated noscapine analogs decreased inflamma-
tory responses induced by both LPS (a TLR4-MD-2 ligand) and by
Pam3CSK4 (a TLR2 ligand) suggesting that brominated noscapine
analogs did not exert their anti-inflammatory effect by selectively
inhibiting TLR4 and TLR2 cell surface receptor dimerization.
Unlike paclitaxel that binds human and murine MD-2 [24], the
anti-inflammatory role of brominated noscapines appeared to be
due to effects on tubulin dynamics.
Red-Br-nos Induces Robust Autophagy in Human
Macrophage Cells
The brominated noscapine analogs displayed innate anti-
inflammatory activity with no effect on cellular viability. However,
the underlying mechanism of the exerted anti-inflammatory
activity is not known. Autophagy plays an essential role in cellular
homeostasis and host defense and it is becoming evident that
TLRs are the environmental sensors for autophagy associated with
innate immunity [25,26,27]. Thus, drug-induced autophagy was
investigated as a possible underlying mechanism of the anti-
inflammatory effects of brominated noscapine analogs. Electron
microscopy data showed that brominated noscapine analogs
Figure 1. Molecular structures of noscapine, 9-bromonoscapine (Br-nos), reduced 9-bromonoscapine (Red-Br-nos) and colchicine.
The common dimethoxy phenyl group is shown in red.
doi:10.1371/journal.pone.0009165.g001
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macrophages THP-1 (Figure 7A). This drug-induced autophagy
was also confirmed by immunoblotting for microtubule-associated
protein light chain 3 (LC-3), a well known marker for autophagy
[28,29]. The results demonstrate the conversion of LC3-I, the
cytoplasmic form of LC-3, into LC3-II that incorporates into the
autophagic membrane (Figure 7B). Detection of acidic vesicular
organelles (AVOs) in THP-1 cells treated with Red-Br-nos further
confirmed the drug-induced autophagic activity (Figure 7C).
Further, when autophagy was inhibited by the pharmacological
inhibitor 3-MA, a reduction in anti-inflammatory activity exerted
by brominated noscapine analogs was observed. Murine
RAW264.7 macrophages treated with 3-MA prior to stimulation
with LPS and brominated noscapine analogs released more TNFa
compared to macrophages without the autophagy inhibitor, 3-MA
(Figure 7D). These data suggest that autophagic clearance
mechanisms might be responsible for either dissipating the
cytosolic inflammatory signaling complex before it reaches the
nucleus to induce pro-inflammatory gene expression or might slow
down/decrease protein synthesis leading to reduced release of pro-
inflammatory mediators [30].
Brominated Noscapine Analogs Enhance ROS Release in
Macrophages
Oxidative and respiratory burst are vital cellular functions that
play an important role in homeostasis and host defense.
Oxidative burst leads to the release of highly reactive oxygen
species (ROS) radicals. We have previously shown that
brominated noscapine analog induces a mitochondrially-driven
intrinsic apoptotic cascade by dissipation of the mitochondrial
membrane potential [9,10]. Since changes in mitochondrial
membrane potential are usually associated with increases in ROS
Figure 2. Pre-treatment of murine and human macrophages with brominated noscapine analogs significantly inhibit TLR4 and
TLR2 pathway inflammatory responses. Murine RAW 264.7 and human THP-1 macrophages were treated with 50 mM of noscapine analogs for
4 hrs followed by LPS induction in concentrations ranging from 10-0.31 pM, or Pam3CSK4 in concentrations ranging from 10-0.31 mg/ml overnight.
A- Nitric oxide (NO) release was determined as nitrite accumulation in supernatants detected by the Griess method. B- TNFa release into
supernatants was measured by ELISA. No drug: RAW264.7 cells treated with DMSO (50 mM) alone followed by LPS or Pam3CSK4 induction. Nos:
noscapine followed by the TLR ligand (nitric oxide p value for LPS=0.0016, Pam3CSK4=0.00013 and TNFa p value for LPS=0.002, Pam3CSK4=0.1).
Br-nos: 9-bromonoscapine followed by the TLR ligand (p value,0.00001). Red-Br-nos: Reduced bromonoscapine and the TLR ligand (p
value,0.0001). Unstimulated cells were used as control and these cells were treated either with DMSO only or Br-nos (50 mM) without the TLR ligand.
Error bars represent SD from mean of at least duplicate readings. Data are representative of at least 3 independent experiments. p values were
calculated with reference to no drug values.
doi:10.1371/journal.pone.0009165.g002
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release from LPS-primed human macrophages were investigated
using an enhanced chemiluminescence method [22]. The results
showed that both noscapine and its brominated analogs
enhanced ROS release in LPS primed cells when added just
prior to triggering the respiratory burst, but not in unprimed
macrophages (Figure 8). In contrast, no change in ROS release
was seen when noscapine or its analogs were added to primed
macrophages 2 hr prior to triggering the respiratory burst (data
not shown). The data suggest that the enhanced ROS release
from primed macrophages may perhaps be due to effects of the
drug on mitochondrial membrane potential rather than cellular
signaling and macrophage priming.
Discussion
Noscapinoids bear structural similarity to colchicine, in that
they have a common molecular signature of a dimethoxy phenyl
group (Fig. 1, see groups in red). This study indicates that
brominated noscapine analogs have potent anti-inflammatory
activity in septic and sterile inflammation models, in a dose-
dependent and time-dependent manner. Brominated noscapine
analogs (Br-nos and Red-Br-nos) dampened TLR-mediated TNF-
a and nitric oxide (NO) release in human and murine
macrophages without evidence of cellular toxicity. Brominated
noscapine analogs also inhibited cytokine/chemokine (a non-TLR
ligand) induced inflammation that mimics sterile inflammation.
Figure 3. Co-treatment of murine and human macrophages with brominated noscapine analogs inhibit TLR-induced inflammatory
responses. A: NO release from RAW 264.7 cells co-treated with 50 mM of noscapine and its analogs and varying doses of TLR ligands (LPS, TLR4
ligand or TLR2 ligand Pam3CSK4) overnight. Nitrite accumulation was detected by the Griess method. B: TNFa release from THP-1 human
macrophage like cells co-treated with 50 mM of noscapine and its analogs and TLR ligands as above and incubated overnight. TNFa release was
measured in the supernatants by ELISA. No drug: RAW264.7 cells treated with DMSO (50 mM) alone followed by LPS or Pam3CSK4 induction. For Nos
(noscapine) and the TLR ligands, nitric oxide p value for LPS was=0.03, Pam3CSK4=0.0004 and TNFa p value for LPS=0.0002, Pam3CSK4=0.0004.
For Br-nos (9-bromonoscapine) and the TLR ligands p values were ,0.0001. For Red-Br-nos (Reduced bromonoscapine) and the TLR ligands p values
were ,0.00001. Unstimulated cells were used as control and these cells were treated either with DMSO only or Br-nos (50 mM) without the TLR
ligand. Error bars represent SD from mean of at least duplicate readings. Data are representative of at least 3 independent experiments. p values were
calculated with reference to no drug values.
doi:10.1371/journal.pone.0009165.g003
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PLoS ONE | www.plosone.org 4 February 2010 | Volume 5 | Issue 2 | e9165Figure 4. Dose-dependent anti-inflammatory effects of the brominated noscapine analogs. Nitric oxide release was measured in RAW
264.7 murine macrophages treated with 10, 25 and 50 mM of noscapine analogs for 4 hrs, then stimulated with the TLR4 ligand LPS or the TLR2
ligand Pam3CSK4 and incubated overnight. Nitrite accumulation was detected by the Griess method. Nos: noscapine parent analog (10 mM Nos
concentration, p value for LPS=0.014, Pam3CSK4=0.0007; 25 mM Nos p value for LPS=0.0001, Pam3CSK4=0.00001; 50 mM Nos p values,0.00001).
Br-nos: brominated noscapine analog and TLR ligand (10 mM Br-nos p value for LPS=0.001, Pam3CSK4 p,0.00001; 25 mM Br-nos p value for
LPS=0.0003, Pam3CSK4, p value,0.00001; 50 mM Br-nos p value,0.00001). Red-Br-nos: reduced brominated noscapine and TLR ligand (10, 25 and
50 mM Red-Br-nos p value,0.00001). Unstimulated cells were used as control and were treated with 25 and 50 mM of noscapine analogs. Error bars
represent the SD from the mean of at least duplicate readings. These data is representative of 3 independent experiments. p values were calculated
with reference to no drug values.
doi:10.1371/journal.pone.0009165.g004
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brominated noscapine analogs is not due to a direct inhibition of
TLR-receptor dimerization and signal initiation.
Two major classes of tubulin-binding drugs, namely taxanes
(such as taxol, taxotere) and vincas (vinblastine, vincristine) are
extensively studied. While taxanes overpolymerize and bundle
microtubules into sheets, vinca alkaloids depolymerize microtubules
into soluble tubulin. Owing to their extreme effects on microtu-
bules, both these classes of drugs interfere with microtubular-track
dependent trafficking and cause toxicities such as peripheral
neuropathies, gastrointestinal toxicity and immunosuppression [5].
Unlike taxanes and vincas, noscapine and its analogs subtly
attenuate microtubule dynamics and do not alter the monomer/
polymer ratio of tubulin[6,13], which perhaps is the reason for
their non-toxic properties [7,8,9,10,11,12,13,14,15,16,32]. Re-
cently, we have shown by detailed quantitative analysis that
brominated noscapine (EM011) modulates microtubule dynamics
by increasing the ‘pause’ time of microtubules without affecting
their overall existence [32]. Thus, noscapine and its brominated
noscapine analog has been shown to be non-toxic with ‘kinder and
gentler’ effects on microtubules [33]. Interestingly, they possess
potent anti-inflammatory activity and drug-induced attenuation of
microtubule dynamics might provide a possible mechanism
contributing to dissipating cytosolic signaling thus dampening
inflammatory responses.
Brominated noscapine analogs when added to macrophages
significantly induced autophagy as evident by extensive autoph-
agy-related vacuolation in cytoplasm and upregulation of
microtubule-associated light-chain protein, LC3-II, that integrates
into the autophagic vesicles. Further, the inhibition of autophagy
with 3-MA led to reduced anti-inflammatory activity exerted by
brominated noscapine analogs. Thus, these data suggest that
induction of autophagy is in part mediating the anti-inflammatory
activity of noscapine analogs. Autophagy is a well-recognized
ancient conserved cellular pathway that removes macromolecules,
recycles and degrades unwanted cytoplasmic components [30].
Figure 5. Brominated noscapine analogs dampen sterile inflammation. A: ScCr (TLR4-deficient) and B: RAW264 (TLR4-sufficient) cells were
treated with 50 mM noscapine analogs for 1 hr (left panel) or overnight (right panel) then stimulated with the murine chemokine IP-10 (CXCL10) or
the murine cytokine TNFa in concentrations from 1000-31.2 pg/ml and incubated overnight. NO release was measured in supernatants by the Griess
method. No drug: ScCr cells treated with DMSO and stimulated with murine cytokine TNFa (A); RAW 264.7 cells stimulated with murine chemokine
IP-10 (B). Nos: noscapine and non-TLR ligands TNFa (A) or IP-10 (B). Br-nos: 9-bromonoscapine and non-TLR ligands. Red-Br-nos: Reduced
bromonoscapine and non-TLR ligands. Unstimulated cells were used as control and were treated either with DMSO only or Br-nos (50 mM). Error bars
represent SD from mean of at least duplicate readings. p values were calculated with reference to no drug values and were ,0.0001 for Br-nos and
Red-Br-nos drug treatment and not significant for the parent drug noscapine.
doi:10.1371/journal.pone.0009165.g005
Anti-Inflammatory Noscapinoids
PLoS ONE | www.plosone.org 6 February 2010 | Volume 5 | Issue 2 | e9165The autophagosome fuses with the lytic lysosome to form
autophagolysosomes that degrades engulfed molecules [34].
Recently, the role of autophagy in host defense has become
evident. TLRs are the environmental sensors for autophagy
associated with innate immunity [25,26]. Several recent reports
demonstrate that autophagy, a bulk degradation system, is directly
involved in the control of inflammatory immune responses [30].
Genetic deficiency of Atg16L1, an autophagy protein, results in
amplified inflammatory responses upon TLR stimulation as
demonstrated by increased IL-1b release [30]. Thus, an essential
component of the autophagic machinery, Atg16L1, suppresses
endotoxin-induced intestinal inflammation [30]. Given the
significant induction of autophagy by brominated noscapines, it
is reasonable to speculate that autophagy might play a role in
preventing or controlling inflammation. Thus, the cross-talk
between drug-induced and TLR-mediated autophagic responses
might impact inflammatory responses.
Oxidative and respiratory burst are vital cellular functions that
play an important role in homeostasis and host defense.
Oxidative burst leads to the release of highly reactive oxygen
species (ROS) radicals. Respiratory burst can be triggered by
phagocytosis, drugs and toxins as well as by soluble stimulus like
the protein kinase C activator PMA. ROS contribute to host
defense by killing the invading pathogen and also act as a second
messenger that induce release of chemokines and cytokines. We
have previously reported that host cationic peptides inhibit
cytokine release from macrophages primed with endotoxin but
enhanced ROS release [21]. Although the underlying mecha-
nism for ROS amplification is not clear, these peptides seem to
exert catalytic effect on NADPH oxidases, xanthine oxidase and
cytochrome c. The current study shows that noscapine and its
brominated analogs enhanced ROS release in LPS primed
human macrophage cells but not in unprimed macrophages
Figure 6. Brominated noscapine analogs dampen TLR-mediat-
ed IL-8 release. HEK293 cells stably transfected with human TLR4-MD-
2-CD14 receptors were co-treated with 50 mM of noscapine analogs and
LPS concentrations ranging from 10-0.31 pM and incubated overnight.
IL-8 release in supernatants was determined by ELISA. No drug:
RAW264.7 cells treated with DMSO (50 mM) alone followed by LPS or
Pam3CSK4 induction. Nos: noscapine and the TLR ligand. Br-nos: 9-
bromonoscapine and the TLR ligand. Red-Br-nos: Reduced bromonos-
capine and the TLR ligand. Unstimulated cells were used as control and
were treated either with DMSO only or Br-nos (50 mM) without the TLR
ligand. p values were calculated with reference to no drug values and
were ,0.0001 for Nos, Br-nos and Red-Br-nos drug treatment.
doi:10.1371/journal.pone.0009165.g006
Figure 7. Brominated noscapine analogs induce autophagy in human macrophages. A: Representative electron micrographs of human
macrophage cells THP-1 treated overnight with LPS alone (2 pM concentration) or LPS and reduced bromo-noscapine (50 mM). Drug induced
autophagy was noted with increased vacuolation in the cytoplasm. B: Western blot of autophagy marker LC3 protein in cell pellets shown in panel A.
C: Fluorescence microscopic analysis of THP-1 cells treated for 24 hrs with DMSO (control), Red-Br-nos, LPS, Red-Br-nos and LPS followed by staining
with 1 mg/ml acridine. Note the formation (red fluorescence) of acridine orange–accumulating acidic vesicular organelles (AVOs) in Red-Br-nos treated
cells. D: Mouse TNFa release from RAW264.7 cells treated with the autophagy inhibitor 3-MA (50 mM) prior to stimulation with LPS alone or with
50 mM of Red-Br-nos, Br-nos or Nos. TNFa was measured by ELISA. The data represent two independent experiments. p values were calculated with
reference to no 3-MA inhibitor and were ,0.001 for Nos, Br-nos and Red-Br-nos drug treatment and LPS stimulation.
doi:10.1371/journal.pone.0009165.g007
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noscapinoids are known to influence mitochondrial membrane
potential [9,14], the increase in ROS release may be due to the
decline of mitochondrial transmembrane potential. One of the
triggers for mitochondrial mediated apoptosis is the production
of ROS. Recently, several studies have indicated that ROS also
play a role in induction of autophagy [35]. The functional
relationship between apoptosis (‘self-killing’) and autophagy
(‘self-eating’) is intricate and complex in the sense that, under
certain situations, autophagy constitutes a stress adaptation that
avoids cell death (and suppresses apoptosis), whereas in other
extreme cellular scenarios, it represents an alternative cell-death
pathway [36].
Several reports suggest that unlike conventional tubulin-binding
agents, noscapine and its analogs are devoid of any detectable
toxicity to normal cells [8,9,10,11,12,13,14,15,16,32]. Although
the time-course employed to study inflammatory responses in
macrophages (up to 24 hrs) has shown to preserve cell viability and
no toxicity was observable, the long term effect of noscapine and
its analogs on macrophages is under current investigation in our
laboratory. We are also addressing whether brominated noscapine
analogs differentially modulate genes involved in inflammation
using gene expression profiles.
In summary, brominated noscapine analogs display innate
anti-inflammatory activity without affecting cell viability. Our
data suggest that non-toxic brominated noscapine analogs
perhaps inhibit the pro-inflammatory responses by inducing
autophagy that dampens inflammation by attenuating or
recycling the inflammatory signaling complex. Brominated
noscapine analogs attenuate microtubule dynamics without
altering the monomer/polymer ratio of tubulin [6,32]. Thus,
the anti-inflammatory effect of these non-toxic brominated
noscapine analogs may also be due to a direct affect on tubulin
and the associated slow dynamics might consequently dampen
signal transduction or delay/impede protein transcription. Our
hypothetical mechanism for anti-inflammatory mode of action of
the brominated noscapine analogs is illustrated in a schematic
model (Figure 9). These novel drugs may serve as useful tools to
study the involvement of the microtubular system in inflamma-
tory signaling.
Materials and Methods
Reagents
Noscapine analogs were synthesized according to previously
reported methods [6,7] and dissolved in DMSO. RPMI 1640
medium, Dulbecco’s Eagle medium, fetal bovine serum (FBS),
penicillin/streptomycin, sodium pyruvate and nonessential amino
acids were obtained from Cellgro (Mediatech Herndon, VA).
Autophagy inhibitor 3-methyladenine (3-MA) was purchased from
Sigma (St Louis, MO). Synthetic TLR2 ligand Pam3CSK4,
embryonic kidney 293 HEK-TLR2/6, HEK-TLR2 and HEK-
TLR4-MD2-CD14 stably transfected cells were purchased from
InvivoGen (San Diego, CA). Macrophage cell lines THP-1,
RAW264.7 and 23ScCr were purchased from ATCC.
Cell Cultures
THP-1 human macrophage-like cells were grown in RPMI
1640 with L-glutamate supplemented with 10% FBS, 50 IU/ml of
penicillin, 50 mg/ml of streptomycin, 1% sodium pyruvate and 1%
non-essential amino acids. Culture flasks were incubated at 37uC
with humidity under 5% CO2. Murine macrophages (RAW 264.7,
23ScCr) and human kidney epithelial cells HEK293 were grown
in Dulbecco’s Eagle medium supplemented and incubated as
mentioned above.
LPS Purification and Quantitation
Lipopolysaccharide (LPS) or endotoxin is a well-characterized
TLR4-MD-2 ligand. Endotoxin from the serogroup B Niesseria
meningitidis strain NMB was initially extracted from whole
meningococci by the phenol-water method. The endotoxin
preparations were further purified and quantified as described
[18]. Briefly, residual membrane phospholipids were removed by
repeated extraction of the dried LPS (also known as lipooligo-
saccharide or LOS) samples with 9:1 ethanol:water. The expected
fatty acyl components of 3-OHC12:0, 3-OHC14:0 and C12:0 and
the absence of membrane phospholipids was assessed by mass
spectroscopy (GC-MS) (Dr Russell Carlson, Complex Carbohy-
drate Research Center, University of Georgia, Athens, GA).
Endotoxin stock solutions were prepared in pyrogen free water at
10 nmole/ml concentration and further diluted with endotoxin
free PBS to 1 nmole/ml and 100 pmole/ml with extensive vortex
and sonication prior to each dilution [18,19].
Cellular Activation and Inflammatory Responses
The effect of noscapine analogs was investigated in time-course
and dose-response experiments in well established human and
murine cell lines. Human THP-1 (a macrophage-like cell line),
murine RAW 264.7 (TLR4-sufficient), 23ScCr (TLR4-deficient),
HEK-TLR2/6 and HEK-TLR4-MD2-CD14 stably transfected
cell lines were treated with noscapine or its analogs at 10, 25 and
50 mM for either 1, 2, 4 hr or overnight prior to stimulation with
TLR ligands mimicking septic inflammation or non-TLR ligands
mimicking sterile inflammation. Alternatively, cells were co-treated
withnoscapineoritsanalogs(50 mM)andTLRligandsornon-TLR
ligand e.g. recombinant cytokines/chemokines were then incubated
overnight. TLR ligand concentrations ranging from (LPS: 10-0.31
picomolar (pM) and Pam3CSK4: 10-0.31 mg/ml) and non-TLR
ligands (mouse IP-10 and TNFa: 1000-31 pg/ml) were made in
duplicatewellsusingsterilePBSbyserialfolddilutionsinthe96-well
tissue culture plates at 50 ml final volumes. Freshly grown THP-1
cells, RAW264.7, ScCr, HEK-TLR2/6 and HEK-TLR4-MD2-
CD14 transfected cells each adjusted to 10
6 cell/ml and 250 ml
aliquots were dispensed into each well at a final cell density of
250610
3 in the designated 96-well plates. The plates were then
Figure 8. Noscapine analogs enhanced ROS release. ROS
release from THP-1 macrophages primed with LPS (1 pM)
overnight. Noscapine analogs (50 mM) were added just prior to a
respiratory burst triggered with PMA (1 mM). ROS release was detected
with the chemiluminescent probe lucigenin. p values were calculated
with reference to no drug but LPS treated cells and were ,0.002.
doi:10.1371/journal.pone.0009165.g008
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Supernatants from stimulated cells were harvested and stored at
220uC until further use. In certain experiments THP-1 and
RAW264.7 cells were pretreated with 50 mM of 3-MA, the
pharmacological inhibitor of autophagy, for 30 min prior to co-
treatment with TLR ligand and brominated noscapine analogs.
Cytokine and Chemokine Profiles
Released cytokines TNFa and IL-6 and chemokines CXCL10
(IP-10), MIP-2a and IL-8 were quantified by DuoSet ELISA
(R&D Systems, Minneapolis, MN) following the manufacturer’s
instructions as previously described [19].
Nitric Oxide Induction by Murine Macrophages
Freshly grown adherent RAW 246.7 or 23ScCr (TLR4-
deficient) macrophages were scraped by a cell scraper. Harvested
cells were washed and re-suspended in Dulbecco’s complete
media, counted and adjusted to 10
6 cell/ml. 250 ml aliquots were
then dispensed into each well at final 250610
3 cell density in the
designated 96-well plates prior to stimulation with TLR ligands or
recombinant cytokines as mentioned above. The induced RAW
264.7 or 23ScCr macrophages were incubated overnight at 37uC
with 5% CO2 and supernatants were harvested and saved. Nitric
oxide release was quantified using the Griess chemical method as
previously described [18].
Cellular Viability and Proliferation Assessment
The toxicity of noscapine or its analogs was determined by
assessing cellular viability and proliferation using trypan blue
exclusion method [20]. Cells were grown at a starting density of
0.75 million cell/ml (final volume 2 ml) in presence of increasing
doses (10, 25 and 50 mM/10
6 cells) of noscapine or its analogs for
3 days. Cellular aliquots (100 ml) were taken daily and cells were
diluted 1:1 with the vital dye trypan blue 0.4% solution (Cellgro,
Mediatech Inc, Herndon, VA) in PBS and viable cells were
counted. LDH release into the supernatant was also measured to
assess the toxicity of the drugs. Light microscopy imaging was used
to assess cellular morphology of macrophages incubated with or
without brominated noscapine analogs [21].
Cellular Respiratory Burst (Oxidative Burst) Activity
The enhanced chemiluminescence method was used as
previously described [22]. Briefly, freshly grown THP-1 cells were
adjusted to 2610
6/ml, transferred to two large tissue culture flasks
labeled as primed or unstimulated. Two pmole/ml LPS were
added to prime cells or left unstimulated as control cells. Both
flasks were incubated overnight at 37uC under 5% CO2. Primed
and control cells were then aliquoted into designated small tissue
culture flasks (25 ml volume) and treated with 50 mM of noscapine
or its analogs or DMSO for 2 hr or instantly prior to triggering
oxidative burst. Unprimed or control cells were also treated with
50 mM of noscapine or its analogs and incubated in the same way
but without endotoxin. The cells were collected in universal tubes,
washed twice with culture medium and resuspended in standard
buffer (4.58 mM KH2PO4, 8.03 mM NaHPO4, 0.5 mM MgCl2,
0.45 mM CaCl2, 1% (w/v) glucose, 0.033% (w/v) KCl, 0.76%
(w/v) NaCl and 0.1% (w/v) endotoxin-free bovine serum albumin
(pH 7.3) at 2610
6/ml. The chemiluminescence probe lucigenin
Figure 9. Schematic presentation of TLR4/MD-2 induced inflammation and hypothetical mode of action for the drug induced anti-
inflammatory effect. Brominated noscapine analogs exert anti-inflammatory effect by interfering with targets either at 1-cell surface receptor
ligation, 2- abrogating signal transduction by attenuating microtubule dynamics and/or by inducing autophagy, 3-inhibiting gene transcription in
the nucleus. TLR4/MD-2 signaling model is adapted from Park et al., 2009 [36] and the embedded images are from the current study.
doi:10.1371/journal.pone.0009165.g009
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1.0 mM stock solution) and mixed gently. Aliquots (150 ml) of the
cellular mixture were transferred into at least quadruplicate wells
of a white 96-well plate (FluoroNunc-PolySorp; Nalge Nunc
International, Rochester, NY). The respiratory burst was triggered
with 50 ml of PMA (1 mM). Chemiluminescence was measured in
relative light units (a measure of the number of photons generated
by the reaction at each time point). Chemiluminescence was
measured using a luminometer (ML3000, Dynatech Laboratories
Inc. Chantilly, Virginia) and the plate was read immediately and
then at 2 min intervals for the next 90 min [22].
Electron Microscopy
Human macrophage cells were fixed for 1 hr with 2%
glutaraldehyde in 0.1 M sodium cacodylate buffer, rinsed in the
same buffer and the post-fixed with 2% osmium tetroxide in the
same buffer for 1 hr at room temperature. The samples were then
dehydrated with a graded ethanol series through 3X 100%, 2X in
propylene oxide and embedded in Spurr’s resin. Sections were
stained with 1% uranyl acetate and lead citrate. Electron
microscopy imaging was then performed at a magnification of
3597X.
Detection of Acidic Vesicular Organelles (AVOs)
THP-1 cells were plated on cover slips and allowed to attach.
Following treatments for 24 hr with DMSO alone (control), Red-
Br-nos, LPS, Red-Br-nos and LPS, cells were stained with 1 mg/ml
acridine orange for 15 min, washed with PBS, and examined under
a Zeiss fluorescence microscope using a 40X objective lens [23].
Western Blot Analysis
Proteins from THP-1 cells pellets were resolved by polyacryl-
amide gel-electrophoresis and transferred onto polyvinylidene
difluoride membranes (Millipore). The membranes were blocked
in Tris-buffered saline containing 0.2% Tween-20 and 5% fat-free
dry milk and incubated first with primary antibodies (LC3 and b-
actin, Cell Signaling) and then with horseradish peroxidase-
conjugated secondary antibodies (Santa-Cruz). Specific proteins
were visualized with enhanced chemiluminescence detection
reagent according to the manufacturer’s instructions (Pierce
Biotechnology).
Statistical Analysis
Mean values of at least 4 independent determinations 6 SD and
p values (Student t test) were calculated in reference to no drug
treatment values using the Excel software.
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